SCHEMBL13596189

SCHEMBL13596189

CCCc1ccc(OCCOCc2cccc(NC(N)=O)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 2/20 0.46
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.44
KMT2A Q03164 1/20 0.44
FFAR1 O14842 1/20 0.43
MDH1 P40925 2/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
NR1H4 Q96RI1 2/20 0.43
PSMB5 P28074 1/20 0.43
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADRB2 P07550 2/20 0.42
ADRB1 P08588 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13072319 0.94 MDH1 (0.51) ALDH1A1KMT2AMDH1NR1H4ADRB2
SCHEMBL13076917 0.88 NR1H4 (0.45) NPC1NR1H4ADRB2ADRB1ADRB3
SCHEMBL8883356 0.79 SIGMAR1 (0.62) NLRP3ALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL13595505 0.78 NR1H4 (0.46) ALDH1A1NPC1KMT2ANR1H4MAPT
SCHEMBL5282403 0.75 ADRB2 (0.74) ADRB2ADRB1ADRB3
SCHEMBL5282390 0.75 ADRB2 (0.74) ADRB2ADRB1ADRB3
SCHEMBL6836303 0.74 THRB (0.71) ALDH1A1KMT2ANR1H4MAPTHSD17B10
SCHEMBL6474766 0.74 SENP1 (0.48) NLRP3NPC1KMT2AFFAR1NR1H4
SCHEMBL6836848 0.71 S1PR1 (0.53) NPC1MDH1GRIN2DGRIN3BGRIN1
SCHEMBL5031452 0.70 SIGMAR1 (0.60) ALDH1A1NPC1KMT2AGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318396-A1 CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY GILEAD SCIENCES, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318396-A1 CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY ADRB1, ADRB2, ADRB3 NLRP3 3372/4885ALDH1A1 4153/4885NPC1 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.